Cathepsin K Discovery Program Designates Candidate Drug (CD)
Medivir announces today that an orally active, small molecule inhibitor of Cathepsin K has been selected as a Candidate Drug (CD). The designation of a CD in the Cathepsin K program is an important milestone for the project and paves the way towards clinical trials. Cathepsin K is a key protease (protein processing enzyme) whose activity regulates skeletal break down. The project goal is to develop a drug that reduces excessive bone degradation. In disease models, Medivir has shown that the pathological resorption (break down) of bone can be dose dependently suppressed if cathepsin K